University of the Sciences is hosting an informative three-part lecture series focusing on Comparative Effectiveness Research (CER): a single step among the advances in medicine that seeks to better understand “value” at the patient level. The aim of the lecture series is to introduce the campus to the concept of CER and build a foundation of knowledge.
“After more than three decades of double digit growth in healthcare spending, CER is the next logical step, and likely not the last,” said Dr. Andrew Peterson, dean of USciences’ Mayes College of Healthcare Business and Policy. “The aging population, increase in covered lives, and most notably a vast array of advances in healthcare technology, have inevitably lead us to the point of needing a far more practical and ‘real world’ understanding of how different treatment choices can impact patient level outcomes.”
At the conclusion of the series, Mayes College will hold its annual program Making the Connections program, this year focusing on The New 4Ps of CER - Pharma, Payer, Provider, & Patient, on Tuesday, April 16 at 5:30 p.m. as part of the events during inauguration week.
Events will be held throughout the University of the Sciences campus.
|Comparative Effectiveness Research Lecture Series
|Date & Location
|January 30, 2013
5 to 6 p.m.
Pharmacology/Toxicology Center (PTC), room 140
|CER and HTA/HIT: Changing the Landscape
||Jean Paul Gagnon, PhD
Secretary, Board of Directors, Dossia
|February 28, 2013
1 to 2 p.m.
McNeil Science and Technology Center (STC), AstraZeneca Auditorium
| CER and Real World Data—What does it mean to the Health Care Professional
|| Marcus Wilson, PharmD
|March 28, 2013
1 to 2 p.m.
|Looking to the Future: CER 2014 and beyond
||Sandy Schwartz, MD
Leon Hess Professor in Internal Medicine, University of Pennsylvania
|Making the Connections
|April 16, 201
5:30 to 8:30 p.m.
McNeil STC, AstraZeneca Auditorium
|The New 4Ps of CER: Pharma, Payer, Provider, & Patient
||Speaker panel TBA
|Made possible by an unrestricted educational grant from AstraZeneca Pharmaceuticals.